查尔斯河实验室(CRL)股价今日盘中大涨21.9%,引发市场关注。公司此前上调了2024年全年利润预期,成为推动股价大涨的主要原因。
根据公告,CRL预计2024年调整后全年每股收益将达到10.10至10.30美元,较之前的9.90至10.20美元区间有所提高。公司还将全年收入预期下滑幅度从2.5%至4.5%上调至2%至3%。
上调利润预期主要源于生物技术客户对CRL药物发现和开发服务需求趋于稳定。最近加息导致融资环境改善,有望提振生物技术公司对CRL服务的需求。公司CEO詹姆斯·福斯特表示,小型生物技术公司2024年资金状况好转,服务订单和取消订单情况出现稳定迹象,同时大型制药商的总体需求趋势亦未进一步恶化。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.